In simulated trial, FDI achieved mean absolute errors of 1.57 and 0.70 years for predicting MCI, AD onset, respectively.

The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...

(HealthDay News) — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Association and the Society for Nuclear Medicine ...

James Cook University researchers will trial a new way of caring for Torres Strait Islanders in an attempt to bring down high rates of dementia in the ...

Discover the surprising link between mouth bacteria and cognitive function. Learn how oral health may play a role in brain ...

ISLAMABAD: A centre set up by the Metropolitan Corporation Islamabad (MCI) to neuter and vaccinate stray dogs is struggling ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

Both amyloid and tau PET are considered appropriate for patients presenting with mild cognitive impairment (MCI) or dementia who are younger ... which is essential to high quality care and treatment ...

which is being operated by the MCI’s Directorate of Municipal Administration (DMA) through its own staff. DMA Deputy Director Mohammad Asif claimed that dogs were being taken care of with the ...

Actor Shivarajkumar returned home to a warm welcome following his successful bladder cancer surgery in the US. The ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the ...